T
Thomas Anthony Hunt
Researcher at AstraZeneca
Publications - 37
Citations - 665
Thomas Anthony Hunt is an academic researcher from AstraZeneca. The author has contributed to research in topics: Epithelial sodium channel & Hydroboration. The author has an hindex of 11, co-authored 33 publications receiving 394 citations. Previous affiliations of Thomas Anthony Hunt include Novartis & University of York.
Papers
More filters
Journal ArticleDOI
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
Stephen T. Durant,Li Zheng,Yingchun Wang,Kan Chen,Lingli Zhang,Tianwei Zhang,Zhenfan Yang,Lucy Riches,Antonio García Trinidad,Jacqueline H. L. Fok,Thomas Anthony Hunt,Kurt Gordon Pike,Joanne Wilson,Aaron Smith,Nicola Colclough,Venkatesh Pilla Reddy,Andrew Sykes,Annika Janefeldt,Peter Johnström,Katarina Varnäs,Akihiro Takano,Stephanie Ling,Jonathan P. Orme,Jonathan Stott,Caroline Roberts,Ian P. Barrett,Gemma N Jones,Martine P. Roudier,Andrew J. Pierce,Jasmine Allen,Jenna M. Kahn,Amrita Sule,Jeremy Karlin,Anna Cronin,Melissa Chapman,Kristoffer Valerie,Ruth Illingworth,Martin Pass +37 more
TL;DR: A pharmacokinetic-pharmacodynamic-efficacy relationship is established by correlating free brain concentrations, tumor phospho-ATM/phospho-Rad50 inhibition, apoptotic biomarker induction, tumor regression, and survival.
Journal ArticleDOI
Hidden Boron Catalysis: Nucleophile-Promoted Decomposition of HBpin.
TL;DR: NMR spectroscopy and kinetic analyses showed that the nucleophiles NaOtBu, Na[N(SiMe3)2], nBu2Mg, and nBuLi only promoted the formation of BH3 and were not "true" hydroboration catalysts.
Journal ArticleDOI
The Hidden Role of Boranes and Borohydrides in Hydroboration Catalysis
TL;DR: The continued development of hydroboration catalysts typifies the importance of this transformation as a testbed for catalytic activity and as a fundamental reaction for organic synthesis as discussed by the authors, and they have been widely used in the literature.
Patent
Bicyclic heteroaryl compounds and their use as kinase inhibitors
TL;DR: The use of PI 3-kinase inhibitors in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases is discussed in this paper.
Journal ArticleDOI
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.
Jeremy Karlin,Jasmine Allen,Syed Farhan Ahmad,Gareth Hughes,Victoria Sheridan,Rajesh Odedra,Paul Farrington,Elaine Cadogan,Lucy Riches,Antonio Garcia-Trinidad,Andrew G. Thomason,Bhavika Patel,Jennifer L. Vincent,Alan Lau,Kurt Gordon Pike,Thomas Anthony Hunt,Amrita Sule,Nicholas C.K. Valerie,Laura Biddlestone-Thorpe,Jenna M. Kahn,Jason M. Beckta,Nitai D. Mukhopadhyay,Barlaam Bernard Christophe,Sébastien L. Degorce,Jason Grant Kettle,Nicola Colclough,Joanne Wilson,Aaron Smith,Ian P. Barrett,Li Zheng,Tianwei Zhang,Yingchun Wang,Kan Chen,Martin Pass,Stephen T. Durant,Kristoffer Valerie +35 more
TL;DR: AZ32 is the first ATMi with oral bioavailability shown to radiosensitize glioma and improve survival in orthotopic mouse models, and support the development of a clinical-grade, BBB-penetrating ATMi for the treatment of GBM.